Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NWL vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NWL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)

NWL Overall Winner 6-Pillar Tally: NWL 3 – 3 SKIN Matrix Metrics: NWL 9 – 1 SKIN

As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NWL carries a Unified Composite Score of 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NWL vs SKIN
NWL NASDAQ Head-to-Head Winner
Newell Brands Inc.
Plastics Products, Nec
$5.85
+1.21% 1D
Market Cap $2.5B
TTM Revenue $7.31B
Forward P/E 8.4x
Beta / 30D Vol 1.28β · 76% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.7 · SMA20: $5.60 · SMA50: $5.62
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (NWL 3 – 3 SKIN)

Columns: Metric · NWL · SKIN
1. Valuation Multiples NWL
Forward P/E 8.4x 106.4x
Trailing P/E 7.9x 106.4x
PEG Ratio 0.97x 0.93x
EV / Revenue 1.0x 0.9x
2. Growth & Scale NWL
Revenue Growth (YoY) +3.7% -2.1%
Earnings Growth (YoY) +126.6% +0.0%
TTM Revenue (USD) $7.31B $289M
Market Cap $2.5B $106.3M
3. Profitability & Quality NWL
Gross Margin 35.1% 67.2%
Operating Margin 7.8% 2.4%
Net Profit Margin -4.4% -6.3%
Return on Equity (ROE) -12.8% -30.1%
4. Balance Sheet & Cash Flow SKIN
Cash Generation (TTM) $53M $17M
Cash Flow Margin 0.7% 5.8%
Net Cash / Leverage $5.12B Net Debt (2.27x D/E) $161M Net Debt (6.61x D/E)
Dividend Yield 4.86% None (0.00%)
5. Options & Positioning SKIN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 46.0% (48th %ile) 517.4% (100th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 27.3% of Rev ($2.00B) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NWL (9) vs SKIN (1)
Institutional Metric NWL SKIN Criterion Row Edge
Market Capitalization
Scale
$2.5B $106.3M Larger Scale NWL
Trailing P/E Ratio
Valuation
7.9x 106.4x Lower Multiple NWL
Forward P/E Ratio
Valuation
8.4x 106.4x Lower Multiple NWL
Revenue Growth (YoY)
Growth
+3.7% -2.1% Higher Growth NWL
Operating Margin (TTM)
Profitability
7.8% 2.4% Higher Margin NWL
Net Profit Margin
Profitability
-4.4% -6.3% Higher Margin NWL
Return on Equity (ROE)
Capital Efficiency
-12.8% -30.1% Higher ROE NWL
52-Week Range Position
Momentum
67% ($3–$7) 83% ($0–$18) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
1.28β · 76% Vol -14.22β · 192% Vol Lower Realized Risk NWL
Unified Institutional Score
Composite Signal
48.5 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite NWL
Trailing 12M Revenue (USD)
Operating Scale
$7.31B $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
35.1% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.97x PEG · 1.0x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$53M ($5.12B Net Debt (2.27x D/E)) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +38.98 pp
NWL: +3.54% · SKIN: +42.52%
3M Horizon SKIN +2409.68 pp
NWL: -1.35% · SKIN: +2408.33%
6M Horizon SKIN +2324.87 pp
NWL: +60.27% · SKIN: +2385.14%
1Y Horizon SKIN +984.61 pp
NWL: +73.08% · SKIN: +1057.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NWL Revenue SKIN Revenue NWL Op. Margin SKIN Op. Margin Margin Leader
FY2018 $10.2B N/A -74.4% N/A NWL
FY2019 $9.71B $170M -5.0% 8.1% SKIN
FY2020 $9.38B $120M -6.7% -14.4% NWL
FY2021 $10.6B $260M 9.6% -15.4% NWL
FY2022 $9.46B $370M 3.3% -7.1% NWL
FY2023 $8.13B $400M -1.0% -32.9% NWL
FY2024 $7.58B $330M 0.9% -20.3% NWL
FY2025 $7.20B $300M 0.5% -6.9% NWL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NWL CONSOLIDATION
74d in phase · OBV NEUTRAL
Current IV 46.0%
IV Percentile 48th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NWL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NWL Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $2.5B market capitalization and 7.8% operating margin.
OpEx & R&D Reinvestment 27.3% of Rev ($2.00B)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ NWL vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, Newell Brands Inc. (NWL) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NWL carries a Unified Composite Score of 48.5/100 (HOLD) at $5.85 (8.4x Forward P/E, 7.8% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Technically, NWL sits in a Neutral phase (RSI 54.7, CONSOLIDATION options structure) and SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure).

NWL leads the Growth & Scale pillar: NWL posts +3.7% YoY revenue growth and +126.6% YoY earnings growth on $7.31B TTM revenue (35.1% gross margin, 7.8% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NWL cumulative revenue shifted -29.1% while SKIN shifted +76.5%. In operating R&D and SG&A reinvestment, NWL deploys 27.3% of Rev ($2.00B) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

NWL screens cheaper on headline valuation multiples. NWL trades at 8.4x Forward P/E, 7.9x Trailing P/E, 0.97x PEG, and 1.0x EV/Revenue (0.7% FCF margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NWL (-12.8% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NWL carries 46.0% implied volatility (48th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 76% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.